Prostate carcinoma is the second most common cause of cancerrelated mortality in males in the United States. The pattern of metastatic disease of prostate cancer is well recognized, frequently involving sclerotic bone lesions and abdominopelvic lymph nodes. Anti-3 F-18 FACBC acid is a synthetic amino acid analog positron emission tomography radiotracer with reported utility in the detection of prostate carcinoma. We present 2 cases of unusual presentations of prostate carcinoma, one with malignant ascites and omental implants and the other with lytic bone lesions detected with anti-3 F-18 FACBC acid.
FIGURE 1.
A 65-year-old man with a history of Gleason 8 (3ϩ5) prostate adenocarcinoma treated with radiation therapy 5 years before presented with a rising PSA (40 ng/mL at presentation, 302 ng/mL on day of anti-3-F-18 FACBC scan) and symptoms of partial bowel obstruction. Anti-3-F-18 FACBC PET/CT performed as part of an ongoing clinical trial with methods previously reported 1,2,7 revealed abnormal uptake in omental implants (SUV max 7.7, small arrows), retroperitoneal lymph nodes (SUV max 7.2, large arrows), and ascites (SUV max 3.1) in axial CT (A), anti-3-F-18 FACBC PET (B), and fused image (C). There was also uptake activity in a 5-cm perirectal mass (SUV max 9.3) and the prostate (SUV max 7.3) (not shown). Patient underwent negative colonoscopy and biopsy with findings of nonspecific mild architectural irregularity of the colonic mucosa. CT-guided FNA of a left paraaortic lymph node was positive for metastatic prostate adenocarcinoma as shown in the 400ϫ histology image of the cell block H & E stain (D) and strongly positive PSA immunostain (E). Cytology of the ascitic fluid also revealed metastatic cells of prostatic origin. Maximum intensity projection image (F) demonstrates typical biodistribution of anti-3-F-18 FACBC 8, 9 with intense hepatic and pancreatic uptake (arrows) and diffuse abdominal uptake secondary to malignant implants and ascites. Advanced prostate carcinoma can present with a wide range of clinical features. The most common sites of metastasis include the axial skeleton, lymph nodes, and lungs. Uncommon sites of metastatic disease include adrenal gland, kidney, brain, pancreas, genitalia, and breasts. 3 Metastasis to the omentum and malignant ascites without bone metastasis as seen in this case are rare presentations. 4 Clinical Nuclear Medicine • Volume 36, Number 9, September 2011 Unusual Presentation of Prostate Carcinoma Metastasis Note relatively little to no bladder excretion (small arrows), which is an advantage of anti-3-F-18 FACBC for prostate cancer imaging. 1, 2, 7 Bone scan (D) showed no evidence of osteoblastic metastatic disease in the axial or appendicular skeleton although bladder may have obscured the lesion. Patient underwent CT-guided biopsy of the right pubic ramus lesion, with a histologic confirmation of metastatic prostate disease as shown in the 400ϫ histology image of the cell block H & E stain (E) and strongly positive PSA immunostain (F). Bone metastasis occurs in about 70% of patients with advanced prostate cancer. 5 Prostate adenocarcinoma metastasis to bone are typically multiple and sclerotic with only about 10% presenting as solitary lesions. 6 Presentation of a purely osteolytic solitary lesion is rare. 6 
